What smart money is saying about Cogent Biosciences Inc
COGT
No fund has written a full thesis on Cogent Biosciences Inc in our archive, but 1 fund letter reports a position in it — most recently Platinium AM in June 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
1
Bought
0
Sold
1
Letter
Position history
Every position in Cogent Biosciences Inc on record in the archive was reported in Q2 2025, across 1 fund letter — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2025 | 1 | 1 | 0 | 0 |
Fund activity · 1 position · 1 move
- AddedPlatinium AMJune 2025
“Reading through M&A activity During the quarter Sanofi acquired Blueprint medicine for over $9b. The Fund has been increasing its position in Blueprint competitor Cogent Biosciences as we feel its drug bezuclastinib is competitive despite worries about its side effect profile.”
Cogent Biosciences Inc
Read the letters behind these Cogent Biosciences Inc positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger